News
Deep Analysis of Bo Lun
It has currently obtained the following honorary titles: Top 10 Chinese Pharmaceutical Outsourcing Companies, Top 10 Most Competitive Enterprises in China's Pharmaceutical Service Industry, National-level "Little Giant" Enterprise Specialized in Specialized, Refined, Differential and Innovative Fields, Guangdong Provincial-level Enterprise Technology Center, Guangdong Postdoctoral Innovation and Practice Base, Top 50 Most Investment-Worthy Enterprises in China, and Honorary Director Unit of the CRO Branch of China Pharmaceutical Quality Management Association (CPQMA).
Deep Analysis of Bo Lun
Deep Analysis of Bo Lun
2024-12-16
他山之石——日本CRO行业如何突破桎梏
2024-09-11
又一新药获批临床！博济医药何以在中药1.2类领域绽放光彩？
2023-06-09
《人遗实施细则》正式发布，对药械临床试验到底影响几何？
2023-05-10
快讯！国家卫健委发布《体细胞临床研究工作指引（征求意见稿）》
2023-04-06
重磅！国家科技部《科技伦理审查办法（试行）》征求意见！
2023-04-10
超43款新药获批！一季度中美新药获批盘点！
2023-03-03
深析博论 | 修订中药说明书，到底怎么办？
2023-03-05
两会划重点！政府工作报告关于“医药健康”都说些啥？
2023-02-17
快讯！CDE连发两文，均涉及药物真实世界研究
2023-01-29